Literature DB >> 2552444

Activity of synthetic peptides from the Tat protein of human immunodeficiency virus type 1.

A D Frankel1, S Biancalana, D Hudson.   

Abstract

To determine which of the 86 amino acids in the Tat protein of human immunodeficiency virus type 1 (HIV-1) are important for transactivation, peptides from Tat were synthesized and their activity was measured in cells containing a chloramphenicol acetyltransferase reporter gene under control of the HIV long terminal repeat promoter. Although the Tat sequence contains arginine- and cysteine-rich stretches that are difficult to synthesize, it was possible to prepare pure peptides in good yield by using fluoren-9-ylmethoxycarbonyl (Fmoc) chemistry. A peptide containing residues 1-58 had 5-10% the activity of full-length Tat. Deleting 4 amino acids from the N terminus of this peptide further reduced activity, while peptides with more extensive N-terminal deletions and peptides missing the basic region at the C terminus had no detectable activity. A peptide previously reported to transactivate, Tat-(37-62), was completely inactive in our assays. Inactive peptides were also tested as possible inhibitors of transactivation. Tat-(21-38), which contains the cysteine-rich region and can form heterodimers with intact Tat in vitro, showed inhibition at high peptide concentrations. However, this effect was not specific for Tat or for the HIV promoter, since the peptide also inhibited expression from the simian virus 40 early promoter.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2552444      PMCID: PMC298069          DOI: 10.1073/pnas.86.19.7397

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  The trans-activator gene of the human T cell lymphotropic virus type III is required for replication.

Authors:  A I Dayton; J G Sodroski; C A Rosen; W C Goh; W A Haseltine
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

2.  The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat.

Authors:  C A Rosen; J G Sodroski; W A Haseltine
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

3.  Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III.

Authors:  J Sodroski; R Patarca; C Rosen; F Wong-Staal; W Haseltine
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

4.  Post-transcriptional regulation accounts for the trans-activation of the human T-lymphotropic virus type III.

Authors:  C A Rosen; J G Sodroski; W C Goh; A I Dayton; J Lippke; W A Haseltine
Journal:  Nature       Date:  1986 Feb 13-19       Impact factor: 49.962

5.  Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a viral sequence encoding 58 amino acids and lacks tissue specificity.

Authors:  L J Seigel; L Ratner; S F Josephs; D Derse; M B Feinberg; G R Reyes; S J O'Brien; F Wong-Staal
Journal:  Virology       Date:  1986-01-15       Impact factor: 3.616

6.  Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression.

Authors:  M Green; M Ishino; P M Loewenstein
Journal:  Cell       Date:  1989-07-14       Impact factor: 41.582

7.  HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA.

Authors:  M B Feinberg; R F Jarrett; A Aldovini; R C Gallo; F Wong-Staal
Journal:  Cell       Date:  1986-09-12       Impact factor: 41.582

8.  Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat.

Authors:  J Sodroski; C Rosen; F Wong-Staal; S Z Salahuddin; M Popovic; S Arya; R C Gallo; W A Haseltine
Journal:  Science       Date:  1985-01-11       Impact factor: 47.728

9.  Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism.

Authors:  B R Cullen
Journal:  Cell       Date:  1986-09-26       Impact factor: 41.582

10.  Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

Authors:  S K Arya; C Guo; S F Josephs; F Wong-Staal
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

View more
  32 in total

1.  Molecular dynamics simulations on HIV-1 Tat.

Authors:  Sergio Pantano; Mudit Tyagi; Mauro Giacca; Paolo Carloni
Journal:  Eur Biophys J       Date:  2003-11-08       Impact factor: 1.733

2.  Activity of synthetic tat peptides in human immunodeficiency virus type 1 long terminal repeat-promoted transcription in a cell-free system.

Authors:  J Jeyapaul; M R Reddy; S A Khan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

3.  The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation.

Authors:  M B Feinberg; D Baltimore; A D Frankel
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

4.  Transcellular transactivation by the human immunodeficiency virus type 1 tat protein.

Authors:  D E Helland; J L Welles; A Caputo; W A Haseltine
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

5.  Identification of lentivirus tat functional domains through generation of equine infectious anemia virus/human immunodeficiency virus type 1 tat gene chimeras.

Authors:  R Carroll; L Martarano; D Derse
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

6.  Analysis of the transcription pattern and mapping of the putative rev and env splice junctions of bovine immunodeficiency-like virus.

Authors:  M S Oberste; J D Greenwood; M A Gonda
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

7.  Binding sites of the viral RNA element TAR and of TAR mutants for various peptide ligands, probed with LILBID: a new laser mass spectrometry.

Authors:  Nina Morgner; Hans-Dieter Barth; Bernhard Brutschy; Ute Scheffer; Sven Breitung; Michael Göbel
Journal:  J Am Soc Mass Spectrom       Date:  2008-07-03       Impact factor: 3.109

8.  A novel human immunodeficiency virus type 1 protein, tev, shares sequences with tat, env, and rev proteins.

Authors:  D M Benko; S Schwartz; G N Pavlakis; B K Felber
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

9.  A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat.

Authors:  L Pearson; J Garcia; F Wu; N Modesti; J Nelson; R Gaynor
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

10.  Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein.

Authors:  T C Rodman; S E To; H Hashish; K Manchester
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.